FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507983749> ?p ?o ?g. }

• W2507983749 endingPage "907" @default.
• W2507983749 startingPage "899" @default.
• W2507983749 abstract "Abstract Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10–100 mg orally twice daily on days 1–8, 1–14, or 1–21 along with continuous infusion topotecan 1.0–1.2 mg/m2/d + carboplatin 120–150 mg/m2/d on days 3–7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage–induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27–0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias. Clin Cancer Res; 23(4); 899–907. ©2016 AACR." @default.
• W2507983749 created "2016-09-16" @default.
• W2507983749 creator A5002822530 @default.
• W2507983749 creator A5007801126 @default.
• W2507983749 creator A5012395020 @default.
• W2507983749 creator A5015341987 @default.
• W2507983749 creator A5016810759 @default.
• W2507983749 creator A5020575293 @default.
• W2507983749 creator A5036285787 @default.
• W2507983749 creator A5038831545 @default.
• W2507983749 creator A5040758762 @default.
• W2507983749 creator A5045409088 @default.
• W2507983749 creator A5045709974 @default.
• W2507983749 creator A5046719320 @default.
• W2507983749 creator A5048801471 @default.
• W2507983749 creator A5052920087 @default.
• W2507983749 creator A5054370710 @default.
• W2507983749 creator A5078527108 @default.
• W2507983749 creator A5085360755 @default.
• W2507983749 creator A5089694123 @default.
• W2507983749 creator A5090468019 @default.
• W2507983749 creator A5091275921 @default.
• W2507983749 date "2017-02-14" @default.
• W2507983749 modified "2023-10-16" @default.
• W2507983749 title "A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia" @default.
• W2507983749 cites W107239320 @default.
• W2507983749 cites W1603401075 @default.
• W2507983749 cites W1973268287 @default.
• W2507983749 cites W1980738402 @default.
• W2507983749 cites W1980766285 @default.
• W2507983749 cites W1992397774 @default.
• W2507983749 cites W1996742853 @default.
• W2507983749 cites W2009007206 @default.
• W2507983749 cites W2009114635 @default.
• W2507983749 cites W2015985237 @default.
• W2507983749 cites W2018562293 @default.
• W2507983749 cites W2042453360 @default.
• W2507983749 cites W2045153367 @default.
• W2507983749 cites W2045448921 @default.
• W2507983749 cites W2056116861 @default.
• W2507983749 cites W2060550559 @default.
• W2507983749 cites W2073025417 @default.
• W2507983749 cites W2074064462 @default.
• W2507983749 cites W2076585941 @default.
• W2507983749 cites W2086038769 @default.
• W2507983749 cites W2094666871 @default.
• W2507983749 cites W2095687961 @default.
• W2507983749 cites W2098737737 @default.
• W2507983749 cites W2110017381 @default.
• W2507983749 cites W2116858301 @default.
• W2507983749 cites W2119574577 @default.
• W2507983749 cites W2131585462 @default.
• W2507983749 cites W2131670056 @default.
• W2507983749 cites W2131674211 @default.
• W2507983749 cites W21378047 @default.
• W2507983749 cites W2140010849 @default.
• W2507983749 cites W2142658272 @default.
• W2507983749 cites W2143942325 @default.
• W2507983749 cites W2156348037 @default.
• W2507983749 cites W2159507916 @default.
• W2507983749 cites W2160220971 @default.
• W2507983749 cites W2160649777 @default.
• W2507983749 cites W2165848530 @default.
• W2507983749 cites W2171972386 @default.
• W2507983749 cites W2173261030 @default.
• W2507983749 cites W2235405584 @default.
• W2507983749 cites W2281441010 @default.
• W2507983749 cites W2296857019 @default.
• W2507983749 cites W2304067133 @default.
• W2507983749 cites W2396559747 @default.
• W2507983749 cites W2538623084 @default.
• W2507983749 doi "https://doi.org/10.1158/1078-0432.ccr-16-1274" @default.
• W2507983749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5315611" @default.
• W2507983749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27551000" @default.
• W2507983749 hasPublicationYear "2017" @default.
• W2507983749 type Work @default.
• W2507983749 sameAs 2507983749 @default.
• W2507983749 citedByCount "32" @default.
• W2507983749 countsByYear W25079837492017 @default.
• W2507983749 countsByYear W25079837492018 @default.
• W2507983749 countsByYear W25079837492019 @default.
• W2507983749 countsByYear W25079837492020 @default.
• W2507983749 countsByYear W25079837492021 @default.
• W2507983749 countsByYear W25079837492022 @default.
• W2507983749 countsByYear W25079837492023 @default.
• W2507983749 crossrefType "journal-article" @default.
• W2507983749 hasAuthorship W2507983749A5002822530 @default.
• W2507983749 hasAuthorship W2507983749A5007801126 @default.
• W2507983749 hasAuthorship W2507983749A5012395020 @default.
• W2507983749 hasAuthorship W2507983749A5015341987 @default.
• W2507983749 hasAuthorship W2507983749A5016810759 @default.
• W2507983749 hasAuthorship W2507983749A5020575293 @default.
• W2507983749 hasAuthorship W2507983749A5036285787 @default.
• W2507983749 hasAuthorship W2507983749A5038831545 @default.
• W2507983749 hasAuthorship W2507983749A5040758762 @default.
• W2507983749 hasAuthorship W2507983749A5045409088 @default.
• W2507983749 hasAuthorship W2507983749A5045709974 @default.
• W2507983749 hasAuthorship W2507983749A5046719320 @default.

• next